HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Bryan, J. P. Articles by Der, C. J. Search for Related Content PubMed PubMed Citation Articles by O'Bryan, J. P. Articles by Der, C. J. Social Bookmarking                      What's this?

J Biol Chem, Vol. 273, Issue 32, 20431-20437, August 7, 1998

The Src Homology 2 and Phosphotyrosine Binding Domains of the ShcC Adaptor Protein Function as Inhibitors of Mitogenic Signaling by the Epidermal Growth Factor Receptor

From the Department of Pharmacology, CB 7365, University of North Carolina, Chapel Hill, North Carolina 27599

Upon ligand activation, the epidermal growth factor receptor (EGFR) becomes tyrosine-phosphorylated, thereby recruiting intracellular signaling proteins such as Shc. EGFR binding of Shc proteins results in their tyrosine phosphorylation and subsequent activation of the Ras and Erk pathways. Shc interaction with activated receptor tyrosine kinases is mediated by two distinct phosphotyrosine interaction domains, an NH₂-terminal phosphotyrosine binding (PTB) domain and a COOH-terminal Src homology 2 (SH2) domain. The relative importance of these two domains for EGFR binding was examined by determining if expression of the isolated SH2 or PTB domain of ShcC would inhibit EGFR signaling. The SH2 domain potently inhibited numerous aspects of EGFR signaling including activation of Erk2 and the Elk-1 transcription factor as well as EGFR-dependent transformation. Furthermore, the SH2 domain inhibited focus formation by the Neu oncoprotein, another EGFR family member. Surprisingly, inhibition of the EGFR by the SH2 domain did not involve stable association with the receptor. In contrast, the PTB domain associated quite well with the receptor yet had little effect on EGFR signaling. Although the EGFR cytoplasmic tail contains consensus binding sites for the PTB and SH2 domains of ShcC, and both domains of ShcC interact with the receptor in vitro, the SH2 domain is more potent for inhibiting receptor function in vivo. However, inhibition is not due to stable association with the receptor, suggesting that the SH2 domain is binding to a heretofore unknown protein(s) necessary for proper EGFR function.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				R. P. Mohney, M. Das, T. G. Bivona, R. Hanes, A. G. Adams, M. R. Philips, and J. P. O'Bryan Intersectin Activates Ras but Stimulates Transcription through an Independent Pathway Involving JNK J. Biol. Chem., November 21, 2003; 278(47): 47038 - 47045. [Abstract] [Full Text] [PDF]

				J.-i. Abe and B. C. Berk Hypoxia and HIF-1{alpha} Stability: Another Stress-Sensing Mechanism for Shc Circ. Res., July 12, 2002; 91(1): 4 - 6. [Full Text] [PDF]

				G. P. Amorino, V. M. Hamilton, K. Valerie, P. Dent, G. Lammering, and R. K. Schmidt-Ullrich Epidermal Growth Factor Receptor Dependence of Radiation-induced Transcription Factor Activation in Human Breast Carcinoma Cells Mol. Biol. Cell, July 1, 2002; 13(7): 2233 - 2244. [Abstract] [Full Text] [PDF]

				D. J. Dunican, E. J. Williams, F. V. Howell, and P. Doherty Selective Inhibition of Fibroblast Growth Factor (FGF)-stimulated Mitogenesis by a FGF Receptor-1-derived Phosphopeptide Cell Growth Differ., May 1, 2001; 12(5): 255 - 264. [Abstract] [Full Text] [PDF]

				A. Adams, J. M. Thorn, M. Yamabhai, B. K. Kay, and J. P. O'Bryan Intersectin, an Adaptor Protein Involved in Clathrin-mediated Endocytosis, Activates Mitogenic Signaling Pathways J. Biol. Chem., August 25, 2000; 275(35): 27414 - 27420. [Abstract] [Full Text] [PDF]